GAPDHP22

Across TCGA pan-cancer cohorts, GAPDHP22 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of GAPDHP22’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where GAPDHP22 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GAPDHP22 is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

COAD, LUAD, and KIRC are the cancer types where GAPDHP22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GAPDHP22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	All	All	+0.369	<.001	8	view →
LUAD	All	All	+0.198	<.001	7	view →
KIRC	Male	II,III,IV	−0.125	<.001	7	view →
LUSC	All	All	+0.300	<.001	5	view →
STAD	All	All	+0.281	.004	5	view →
CHOL	All	II,III,IV	+0.605	<.001	4	view →
ESCA	All	II,III,IV	+0.690	.014	2	view →
BLCA	All	All	+0.246	.041	2	view →
HNSC	All	III,IV	+0.152	.037	1	view →
LIHC	Male	All	+0.095	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

GAPDHP22–COAD

Open the COAD breakdown →